We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project
News

NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project

NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project
News

NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NovAliX SAS announced today that it has entered into a fragment-based drug discovery project with Kyowa Hakko Kirin Co., Ltd., Japan. This is a continuation of the alliance announced on January 14 of this year and builds upon the positive results already generated by the NovAliX biophysical platform.   

First, NovAliX will generate lead candidates using its Graffinity® screening platform. The ensuing "hits" will be elaborated by NovAliX' in-house teams of biophysical and chemistry experts. The biophysical toolbox encompasses a broad spectrum of instrumental techniques employed iteratively to support the activities of synthetic organic, computational and medicinal chemists.  

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.  

Stephan Jenn, President of NovAliX, stated, ”We in NovAliX are highly excited by this important development in our relationship with Kyowa Hakko Kirin. The collaboration with a leading Japanese pharmaceutical company underlines the value offered by the NovAliX integrated drug discovery platforms; platforms designed and proven to deliver not only hits and but also optimized lead compounds. The extension of the drug discovery alliance to another target validates our capabilities.”

Advertisement